Related Party Transactions |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Related Party Transactions [Abstract] | |
| Related Party Transactions | 11. Related-Party Transactions Jefferies Sales Agreement John Maraganore is a member of the Company’s Board of Directors, and is affiliated with Jefferies LLC (“Jefferies”). On October 31, 2024, prior to Dr. Maraganore joining Jefferies, the Company entered into an Open Market Sale AgreementSM (the “Jefferies Sales Agreement”) with Jefferies, pursuant to which the Company may offer and sell shares of its common stock having aggregate gross proceeds of up to $300.0 million from time to time in “at-the-market” offerings through Jefferies, as its sales agent. The Company agreed to pay Jefferies a commission of up to 3.0% of the gross proceeds of any shares sold by Jefferies under the Jefferies Sales Agreement. On February 26, 2026, Jefferies acknowledged and accepted the Company's prior written notice to terminate the Jefferies Sales Agreement, which termination was effective on February 26, 2026. As a result of such termination, the Company will not offer or sell any additional shares of common stock under the Jefferies Sales Agreement and as of its termination, the Company had not sold any shares of its common stock under the Jefferies Sales Agreement. Related Party Sublease On July 14, 2026, the Company entered into a sublease agreement (the "Sublease") with Merida Biosciences, Inc. ("Merida"), pursuant to which the Company subleased the office/laboratory space governed by the 2019 Lease to Merida. Merida is considered a related party because one of the Company's directors, John Maraganore, also serves as a member of Merida's board of directors. The terms of the Sublease were reviewed and approved by the Company's Audit Committee in accordance with the Company's related party transaction policy. Management believes the terms of the Sublease are consistent with those that would have been negotiated with an unrelated third party. Other than the aforementioned agreement, the Company had no related party transactions for the periods presented in the accompanying consolidated financial statements, which have not otherwise been discussed in these notes to the consolidated financial statements. |